# Altimmune (ALT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ALT
## Company Profile
- Ticker: ALT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 2.93 USD
- Market cap: 563975046.6 USD
- Last updated: 2026-08-12
## Business Overview
### Metabolic and Liver Disease Company
Altimmune develops pemvidutide for serious metabolic and liver diseases.
### Balanced Dual Agonist
Pemvidutide is a balanced glucagon and GLP-1 receptor agonist intended to combine weight loss with direct effects on liver fat, inflammation, and lipid metabolism.
### MASH Program
The global PERFORMA program is designed to evaluate pemvidutide as a Phase 3 treatment for metabolic dysfunction-associated steatohepatitis.
### Alcohol-Related Disease
The RECLAIM study evaluates pemvidutide in alcohol use disorder, with potential expansion into alcohol-associated liver disease.
## Why The Stock Is Moving

Following the latest company update, “Altimmune Announces Second Quarter 2026 Financial Results and Business Update”, ALT closed down 2.33% at $2.93 on Aug 12, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- The Phase 3 PERFORMA study in MASH is expected to begin in the second half of 2026.
- Topline data from the Phase 2 RECLAIM trial in alcohol use disorder are expected in the third quarter of 2026.
- A 52-week PERFORMA data readout is anticipated in 2029.

## Recent News
- 2026-08-12 11:30 EST — [Altimmune Announces Second Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALT/altimmune-announces-second-quarter-2026-financial-results-and-business-update-b34b0e74) — Source: Altimmune
- 2026-08-05 12:00 EST — [Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026](https://biopharmsignal.com/news/ALT/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-u-2d1960ad) — Source: Altimmune
- 2026-08-03 12:00 EST — [Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH](https://biopharmsignal.com/news/ALT/altimmune-initiates-performa-phase-3-trial-of-pemvidutide-in-patients-with-mash-e85d90c3) — Source: Altimmune
- 2026-07-28 11:00 EST — [Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder](https://biopharmsignal.com/news/ALT/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvi-1fc61fa7) — Source: Altimmune
- 2026-05-28 15:00 EST — [Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026](https://biopharmsignal.com/news/ALT/pemvidutide-demonstrates-significant-metabolic-improvements-in-patients-with-mas-a943260b) — Source: Altimmune